BCYC लाइव सिग्नल्स | Getagraph.com के साथ लाभ को अधिकतम करें

खरीदें 120350 min ago

@ $21.78

जारी किया गया: 15 Feb 2024 @ 00:17

वापसी: 5.99%

पिछला सिग्नल: Feb 14 - 20:00

पिछला सिग्नल: बेचें

वापसी: -1.94 %

Live Chart Being Loaded With Signals

Commentary (8 May 2024 @ 01:30):

Bicycle Therapeutics plc, a clinical-stage biopharmaceutical company, develops a class of medicines for diseases that are underserved by existing therapeutics...

Stats
आज की मात्रा	253 719
औसत मात्रा	406 296
बाजार मूल्य	983.96M
EPS	$0 ( 2024-05-02 )
अगली कमाई की तारीख	( $-1.240 ) 2024-05-16
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-5.25
ATR14	$0.0390 (0.17%)

Insider Trading

Date	Person	Action	Amount	type
2024-04-18	Baker Bros. Advisors Lp	Buy	12 000	American Depositary Shares
2024-04-18	Baker Bros. Advisors Lp	Buy	12 000	American Depositary Shares
2024-04-18	Baker Bros. Advisors Lp	Buy	24 000	Share Option (Right to Buy)
2024-04-18	Baker Bros. Advisors Lp	Buy	0	American Depositary Shares
2024-04-18	Baker Bros. Advisors Lp	Buy	0	American Depositary Shares

INSIDER POWER
72.47
Last 94 transactions
Buy: 1 498 500 \| Sell: 230 741

मात्रा सहसंबंध

लंबा: -0.07 (neutral)

छोटा: 0.77 (moderate)

Signal:(54.113) Neutral

Bicycle Therapeutics PLC सहसंबंध

10 सबसे अधिक सकारात्मक सहसंबंध
GSMG	0.966
SIRI	0.954
SINT	0.953
JAGX	0.951
VWE	0.951
DBGI	0.948
NAKD	0.948
RPTX	0.944
EQ	0.941
YJ	0.941

10 सबसे अधिक नकारात्मक सहसंबंध
INTA	-0.972
AGGR	-0.963
BIOS	-0.96
FICV	-0.959
ALSA	-0.957
TBSA	-0.957
NCAC	-0.956
MLTX	-0.955
PPYAU	-0.955
LVRA	-0.954

क्या आप जानते हैं?

कोरलेशन एक सांख्यिकीय माप है जो दो चरों के बीच संबंध का वर्णन करता है। यह -1 से 1 तक का होता है, जहाँ -1 एक पूर्ण नकारात्मक कोरलेशन को दर्शाता है (जैसे ही एक चर बढ़ता है, दूसरा कम होता है), 1 एक पूर्ण सकारात्मक कोरलेशन को दर्शाता है (जैसे ही एक चर बढ़ता है, दूसरा भी बढ़ता है) और 0 कोई कोरलेशन नहीं होता है (चरों के बीच कोई संबंध नहीं है)।

कोरलेशन किसी भी दो चरों के बीच संबंध का विश्लेषण करने के लिए इस्तेमाल किया जा सकता है, न कि केवल स्टॉक में। यह वित्तीय, अर्थशास्त्र, मनोविज्ञान और अन्य क्षेत्रों में आमतौर पर उपयोग किया जाता है।

Bicycle Therapeutics PLC सहसंबंध - मुद्रा/वस्त्र

0.03
( neutral )

-0.15
( neutral )

0.00
( neutral )

0.15
( neutral )

0.27
( neutral )

0.10
( neutral )

Bicycle Therapeutics PLC वित्तीय

Annual	2023
राजस्व:	$26.98M
सकल लाभ:	$20.40M (75.64 %)
EPS:	$-5.08

FY	2023
राजस्व:	$26.98M
सकल लाभ:	$20.40M (75.64 %)
EPS:	$-5.08

FY	2022
राजस्व:	$14.46M
सकल लाभ:	$10.78M (74.51 %)
EPS:	$-3.80

FY	2021
राजस्व:	$11.70M
सकल लाभ:	$0.00 (0.00 %)
EPS:	$-2.67

Financial Reports:

No articles found.

Bicycle Therapeutics PLC

Bicycle Therapeutics plc, a clinical-stage biopharmaceutical company, develops a class of medicines for diseases that are underserved by existing therapeutics. Its lead product candidate is BT1718, a bicycle toxin conjugate (BTC), which is in Phase I/IIa clinical trials targeting tumors that express Membrane Type 1 matrix metalloprotease. The company's oncology product candidates also comprise BT5528, a BTC that is in a Phase I/II clinical trial targeting EphA2; and BT8009, which is in Phase I/II clinical trial targeting Nectin-4. In addition, it is developing THR-149, a plasma kallikrein inhibitor that completed Phase II clinical trials for the treatment of diabetic macular edema; BT7480, a Bicycle tumor-targeted immune cell agonist (TICA) targeting Nectin-4 and agonizing; BT7455, an EphA2/CD137 Bicycle TICA, which is in preclinical studies; and BT1718, a BTC that target tumors, that is in Phase I/IIa clinical trial that express Membrane Type 1 matrix metalloproteinase. Further, the company collaborates with biopharmaceutical companies and organizations to develop programs in therapeutic areas, such as anti-infective, cardiovascular, ophthalmology, and respiratory indications. It has a clinical trial and license agreement with the Cancer Research Technology Limited and Cancer Research UK; research collaboration agreements with AstraZeneca, Sanofi, Oxurion, and the Dementia Discovery Fund; and discovery collaboration and license agreement with Genentech for the discovery and development of Bicycle peptides for multiple immuno-oncology targets. Bicycle Therapeutics plc was incorporated in 2009 and is headquartered in Cambridge, the United Kingdom.